Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Effects of Physical Exercise on Neuroinflammation, Neuroplasticity, Neurodegeneration, and Behavior: What We Can Learn From Animal Models in Clinical Settings.
Effects of Three Months Fingolimod Therapy on Heart Rate.
Chronic deep brain stimulation for the treatment of tremor in multiple sclerosis: review and case reports.
Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models.
Simple MRI Metrics Contribute to Optimal Care of the Patient with Multiple Sclerosis.
Multiple deep white matter lesions mimicking multiple sclerosis as an unusual complication of a left atrial myxoma.
Infusion of Sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate-Conjugated MOG35-55-Coupled Spleen Cells Effectively Prevents and Reverses Experimental Autoimmune Encephalomyelitis in Mice.
Relevance of brain lesion location to cognition in relapsing multiple sclerosis.
Balance.
Ciliary Neurotrophic Factor Role in Myelin Oligodendrocyte Glycoprotein Expression in Cuprizone-Induced Multiple Sclerosis Mice.
Downbeat nystagmus associated with damage to the medial longitudinal fasciculus of the pons: A vestibular balance control mechanism via the lower brainstem paramedian tract neurons.
Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect?
Hypoperfusion and T1-hypointense lesions in white matter in multiple sclerosis.
Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial.
Alemtuzumab for relapsing-remitting multiple sclerosis.
Longitudinal changes in self-reported walking ability in multiple sclerosis.
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).
Risk of fractures in patients with multiple sclerosis: A population-based cohort study.
Leuprolide Acetate, a GnRH Agonist, Improves Experimental Autoimmune Encephalomyelitis: A Possible Therapy for Multiple Sclerosis.
Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.
Serum levels of LIGHT in MS.
Phase 3 Efficacy and Tolerability Study of OnabotulinumtoxinA for Urinary Incontinence From Neurogenic Detrusor Overactivity.
Tobacco smoking and excess mortality in multiple sclerosis: a cohort study.
Complex assessment in progressive multiple sclerosis: a case report.
Serum lactate as a novel potential biomarker in multiple sclerosis.

Pages